BRIEF-Novan Submits NDA To U.S. FDA For Berdazimer Gel, 10.3%

Jan 6 (Reuters) - Ligand Pharmaceuticals Inc LGND.O:

• LIGAND’S PARTNER NOVAN SUBMITS NEW DRUG APPLICATION TO THE U.S. FDA FOR BERDAZIMER GEL, 10.3% (SB206) FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM

• LIGAND PHARMACEUTICALS INC - POTENTIAL FDA APPROVAL ANTICIPATED IN Q1 OF 2024, ASSUMING FDA FILING ACCEPTANCE AND STANDARD REVIEW TIMELINES

Source text for Eikon: ID:

Further company coverage: LGND.O

((Reuters.Briefs@thomsonreuters.com;))